Friday, November 07, 2014 4:22:54 PM
"Chris,
It was my pleasure and I thank you for the follow up message. We feel strongly that we have accomplished a lot this year to create value in our development programs and we anticipate meaningful updates and clinical data next year (as we guided in our last quarterly report, which I am enclosing with this email). We will continue to actively work to communicate this progress to our existing and potential investors. As I know you can probably appreciate, there certainly has been a slow learning curve around sickle cell disease and the importance of therapies in this significant unmet indication. However, we have seen tremendous interest in the space over the past year and we will continue to actively build awareness and interest in the investment community.
Furthermore, we believe there is a reason we have quality investors like Franklin Advisors and Baker Brothers as some of our largest shareholders and we will continue to work to add additional institutional ownership in Mast. We feel that we are building an exceptional business and are taking the right steps internally to build value by moving the clinical development of our programs across different indications as timely and effectively as possible."
Regards,
Ioana
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM